{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:41:03Z","timestamp":1793932863807,"version":"4.8.0"},"reference-count":25,"publisher":"Bentham Science Publishers Ltd.","issue":"28","funder":[{"DOI":"10.13039\/501100018531","name":"Yunnan Province Science and technology project","doi-asserted-by":"publisher","award":["202201AU070203"],"award-info":[{"award-number":["202201AU070203"]}],"id":[{"id":"10.13039\/501100018531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2019JJ50875"],"award-info":[{"award-number":["2019JJ50875"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900069"],"award-info":[{"award-number":["81900069"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Diabetic nephropathy (DN) is one of the most serious complications\nof diabetes mellitus and the main cause of the end-stage renal disease (ESRD). Activation\nof the NLRP3 inflammasome has been proven to play an important role in the development\nof DN. Thus, specific and direct targets of NLRP3 inflammasome assembly\nmay have therapeutic potential. CY-09 is a new NLRP3 inflammasome specific inhibitor\nthat has been shown to protect against non-alcoholic fatty liver disease (NAFLD) by inhibiting\nthe activation of the NLRP3 inflammasome. However, its role in kidney disease,\nespecially DN, has not been reported.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>In this study, we used HE staining to assess renal pathological damage in each\ngroup, and RT-PCR, immunofluorescence and WB were performed to detect the expression\nchanges in inflammatory and fibrosis proteins. The apoptosis level was detected by\nTUNEL staining.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Here, we showed increased inflammation, oxidative stress, apoptosis and fibrosis\nin db\/db mice, while CY-09 exerted renoprotection by inhibiting NLRP3 inflammasome\nactivation. In vitro, CY-09 also inhibited NLRP3 and reduced caspase-1, IL-18, IL-1\u03b2 and\napoptosis in a dose-dependent manner.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>CY-09 effectively protects the kidney from hyperglycemia induced damage\nby inhibiting the NLRP3 inflammasome and may be a promising therapeutic strategy to\nprevent the progression of DKD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220922104654","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T04:29:43Z","timestamp":1663907383000},"page":"3261-3270","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["The Selective NLRP3-Inflammasome Inhibitor CY-09 Ameliorates\nKidney Injury in Diabetic Nephropathy by Inhibiting NLRP3-\ninflammasome Activation"],"prefix":"10.2174","volume":"30","author":[{"given":"Ming","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second Xiangya Hospital of Central South University, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Reproduction and Genetics, The First Affiliated Hospital of Kunming Medical University,\nKunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41581-019-0135-6","volume":"15","author":"Kato M.","year":"2019","unstructured":"Kato M.; Natarajan R.; Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol 2019,15(6),327-345","journal-title":"Nat Rev Nephrol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","volume":"128","author":"Ogurtsova K.","year":"2017","unstructured":"Ogurtsova K.; da Rocha Fernandes J.D.; Huang Y.; Linnenkamp U.; Guariguata L.; Cho N.H.; Cavan D.; Shaw J.E.; Makaroff L.E.; IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017,128,40-50","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/dme.13416","volume":"34","author":"Jiao F.","year":"2017","unstructured":"Jiao F.; Wong C.K.H.; Tang S.C.W.; Fung C.S.C.; Tan K.C.B.; McGhee S.; Gangwani R.; Lam C.L.K.; Annual direct medical costs associated with diabetes-related complications in the event year and in subsequent years in Hong Kong. Diabet Med 2017,34(9),1276-1283","journal-title":"Diabet Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","volume":"17","author":"Oshima M.","year":"2021","unstructured":"Oshima M.; Shimizu M.; Yamanouchi M.; Toyama T.; Hara A.; Furuichi K.; Wada T.; Trajectories of kidney function in diabetes: A clinicopathological update. Nat Rev Nephrol 2021,17(11),740-750","journal-title":"Nat Rev Nephrol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ndt\/gfp599","volume":"25","author":"Tang S.C.W.","year":"2010","unstructured":"Tang S.C.W.; Chan L.Y.Y.; Leung J.C.K.; Cheng A.S.; Chan K.W.; Lan H.Y.; Lai K.N.; Bradykinin and high glucose promote renal tubular inflammation. Nephrol Dial Transplant 2010,25(3),698-710","journal-title":"Nephrol Dial Transplant"},{"key":"ref=6","first-page":"1322","volume":"32","author":"Klessens C.Q.F.","year":"2017","unstructured":"Klessens C.Q.F.; Zandbergen M.; Wolterbeek R.; Bruijn J.A.; Rabelink T.J.; Bajema I.M.; IJpelaar D.H.T.; Macrophages in diabetic nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 2017,32(8),1322-1329","journal-title":"Nephrol Dial Transplant"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41581-019-0110-2","volume":"15","author":"Tang P.M.K.","year":"2019","unstructured":"Tang P.M.K.; Nikolic-Paterson D.J.; Lan H.Y.; Macrophages: Versatile players in renal inflammation and fibrosis. Nat Rev Nephrol 2019,15(3),144-158","journal-title":"Nat Rev Nephrol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneph.2014.114","volume":"10","author":"Meng X.M.","year":"2014","unstructured":"Meng X.M.; Nikolic-Paterson D.J.; Lan H.Y.; Inflammatory processes in renal fibrosis. Nat Rev Nephrol 2014,10(9),493-503","journal-title":"Nat Rev Nephrol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"Swanson K.V.","year":"2019","unstructured":"Swanson K.V.; Deng M.; Ting J.P.Y.; The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat Rev Immunol 2019,19(8),477-489","journal-title":"Nat Rev Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.redox.2019.101215","volume":"24","author":"Li N.","year":"2019","unstructured":"Li N.; Zhou H.; Wu H.; Wu Q.; Duan M.; Deng W.; Tang Q.; STING-IRF3 contributes to lipopolysaccharide-induced cardiac dys-function, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol 2019,24,101215","journal-title":"Redox Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","volume":"16","author":"Tang S.C.W.","year":"2020","unstructured":"Tang S.C.W.; Yiu W.H.; Innate immunity in diabetic kidney disease. Nat Rev Nephrol 2020,16(4),206-222","journal-title":"Nat Rev Nephrol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/JME-18-0069","volume":"61","author":"Song S.","year":"2018","unstructured":"Song S.; Qiu D.; Luo F.; Wei J.; Wu M.; Wu H.; Du C.; Du Y.; Ren Y.; Chen N.; Duan H.; Shi Y.; Knockdown of NLRP3 alleviates high glucose or TGFB1-induced EMT in human renal tubular cells. J Mol Endocrinol 2018,61(3),101-113","journal-title":"J Mol Endocrinol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.ymthe.2021.03.012","volume":"29","author":"Ding H.","year":"2021","unstructured":"Ding H.; Li J.; Li Y.; Yang M.; Nie S.; Zhou M.; Zhou Z.; Yang X.; Liu Y.; Hou F.F.; MicroRNA-10 negatively regulates in-flammation in diabetic kidney via targeting activation of the NLRP3 inflammasome. Mol Ther 2021,29(7),2308-2320","journal-title":"Mol Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.mce.2018.08.002","volume":"478","author":"Wu M.","year":"2018","unstructured":"Wu M.; Han W.; Song S.; Du Y.; Liu C.; Chen N.; Wu H.; Shi Y.; Duan H.; NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice. Mol Cell Endocrinol 2018,478,115-125","journal-title":"Mol Cell Endocrinol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"Jiang H.","year":"2017","unstructured":"Jiang H.; He H.; Chen Y.; Huang W.; Cheng J.; Ye J.; Wang A.; Tao J.; Wang C.; Liu Q.; Jin T.; Jiang W.; Deng X.; Zhou R.; Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med 2017,214(11),3219-3238","journal-title":"J Exp Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1007\/s11695-020-04571-8","volume":"30","author":"Sun K.","year":"2020","unstructured":"Sun K.; Wang J.; Lan Z.; Li L.; Wang Y.; Li A.; Liu S.; Li Y.; Sleeve gastroplasty combined with the NLRP3 inflammasome inhibi-tor CY-09 reduces body weight, improves insulin resistance and alleviates hepatic steatosis in mouse model. Obes Surg 2020,30(9),3435-3443","journal-title":"Obes Surg"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1111\/bph.14998","volume":"177","author":"Pan L.L.","year":"2020","unstructured":"Pan L.L.; Liang W.; Ren Z.; Li C.; Chen Y.; Niu W.; Fang X.; Liu Y.; Zhang M.; Diana J.; Agerberth B.; Sun J.; Cathelicidin\u2010related antimicrobial peptide protects against ischaemia reperfusion\u2010induced acute kidney injury in mice. Br J Pharmacol 2020,177(12),2726-2742","journal-title":"Br J Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrneph.2018.9","volume":"14","author":"Forbes J.M.","year":"2018","unstructured":"Forbes J.M.; Thorburn D.R.; Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol 2018,14(5),291-312","journal-title":"Nat Rev Nephrol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.redox.2018.02.013","volume":"16","author":"Han Y.","year":"2018","unstructured":"Han Y.; Xu X.; Tang C.; Gao P.; Chen X.; Xiong X.; Yang M.; Yang S.; Zhu X.; Yuan S.; Liu F.; Xiao L.; Kanwar Y.S.; Sun L.; Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ros-txnip-nlrp3 biological axis. Redox Biol 2018,16,32-46","journal-title":"Redox Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1042\/CS20200005","volume":"134","author":"Gao P.","year":"2020","unstructured":"Gao P.; Yang M.; Chen X.; Xiong S.; Liu J.; Sun L.; DsbA-L deficiency exacerbates mitochondrial dysfunction of tubular cells in diabetic kidney disease. Clin Sci (Lond) 2020,134(7),677-694","journal-title":"Clin Sci (Lond)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ebiom.2019.04.044","volume":"43","author":"Yang M.","year":"2019","unstructured":"Yang M.; Zhao L.; Gao P.; Zhu X.; Han Y.; Chen X.; Li L.; Xiao Y.; Wei L.; Li C.; Xiao L.; Yuan S.; Liu F.; Dong L.Q.; Kanwar Y.S.; Sun L.; DsbA-L ameliorates high glucose induced tubular damage through maintaining MAM integrity. EBioMedicine 2019,43,607-619","journal-title":"EBioMedicine"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.kint.2018.10.038","volume":"95","author":"Chen X.","year":"2019","unstructured":"Chen X.; Han Y.; Gao P.; Yang M.; Xiao L.; Xiong X.; Zhao H.; Tang C.; Chen G.; Zhu X.; Yuan S.; Liu F.; Dong L.Q.; Liu F.; Kanwar Y.S.; Sun L.; Disulfide-bond A oxidoreductase-like protein protects against ectopic fat deposition and lipid-related kidney damage in diabetic nephropathy. Kidney Int 2019,95(4),880-895","journal-title":"Kidney Int"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40265-018-0942-2","volume":"78","author":"Afsar B.","year":"2018","unstructured":"Afsar B.; Covic A.; Ortiz A.; Afsar R.E.; Kanbay M.; The future of IL-1 targeting in kidney disease. Drugs 2018,78(11),1073-1083","journal-title":"Drugs"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.3389\/fimmu.2019.02538","volume":"10","author":"Zahid A.","year":"2019","unstructured":"Zahid A.; Li B.; Kombe A.J.K.; Jin T.; Tao J.; Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol 2019,10,2538","journal-title":"Front Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s12264-020-00544-0","volume":"36","author":"Lin H.B.","year":"2020","unstructured":"Lin H.B.; Wei G.S.; Li F.X.; Guo W.J.; Hong P.; Weng Y.Q.; Zhang Q.Q.; Xu S.Y.; Liang W.B.; You Z.J.; Zhang H.F.; Macro-phage\u2013NLRP3 inflammasome activation exacerbates cardiac dysfunction after ischemic stroke in a mouse model of diabetes. Neurosci Bull 2020,36(9),1035-1045","journal-title":"Neurosci Bull"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220922104654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/209074\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220922104654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T20:00:57Z","timestamp":1693684857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/209074\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":25,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220922104654","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}